Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619538 | 0.71 | ADORA2B (0.42) | KDM4ENPSR1ADORA2BALDH1A1POLB | |
| SCHEMBL5204918 | 0.71 | ADORA2B (0.42) | KDM4ENPSR1ADORA2BALDH1A1POLB | |
| SCHEMBL5204925 | 0.71 | ADORA2B (0.42) | KDM4ENPSR1ADORA2BALDH1A1POLB | |
| SCHEMBL6619534 | 0.71 | ADORA2B (0.42) | KDM4ENPSR1ADORA2BALDH1A1POLB | |
| SCHEMBL6931336 | 0.70 | ALDH1A1 (0.42) | KDM4ENPSR1NPC1ADORA2BALDH1A1 | |
| SCHEMBL10567240 | 0.64 | ALDH1A1 (0.48) | KDM4ENPSR1NPC1ALDH1A1GAA | |
| SCHEMBL10794871 | 0.63 | ADORA2B (0.55) | KDM4EADORA2BGAAPOLBL3MBTL1 | |
| SCHEMBL3073309 | 0.63 | ALDH1A1 (0.49) | KDM4ENPSR1ADORA2BALDH1A1GAA | |
| SCHEMBL14492355 | 0.63 | ALDH1A1 (0.62) | KDM4ENPSR1NPC1ADORA2BALDH1A1 | |
| SCHEMBL3073312 | 0.63 | ALDH1A1 (0.49) | KDM4ENPSR1ADORA2BALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423108-B1 | C-2' METHYLATED DERIVATIVES OF PACLITAXEL FOR USE AS ANTITUMOUR AGENTS | INDENA SPA (IT) | 2007-06-06 | — | — | EP | disclosed |
| EP-1423108-B1 | C-2' METHYLATED DERIVATIVES OF PACLITAXEL FOR USE AS ANTITUMOUR AGENTS | INDENA SPA (IT) | 2007-06-06 | — | — | EP | disclosed |
| US-7153884-B2 | C-2′ methylated derivatives of paclitaxel for use as antitumour agents | INDENA S.P.A. (IT) | 2006-12-26 | — | — | US | disclosed |
| US-20040242674-A1 | C-2' methylated derivatives of paclitaxel for use as antitumour agents | INDENA S.P.A. (IT) | 2004-12-02 | — | — | US | disclosed |
| EP-1423108-A1 | C-2' METHYLATED DERIVATIVES OF PACLITAXEL FOR USE AS ANTITUMOUR AGENTS | INDENA S.p.A. (IT) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003013503-A1 | C-2' METHYLATED DERIVATIVES OF PACLITAXEL FOR USE AS ANTITUMOUR AGENTS | INDENA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242674-A1 | C-2' methylated derivatives of paclitaxel for use as antitumour agents | TOP2B, TOP2A, CCAR2 | KDM4E 2848/4885NPSR1 2053/4885NPC1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.